Evidence map›Paper›PMID 29530080›Full record

ArticleAddiction science & clinical practice2018

Substance use and the HIV care continuum: important advances.

P Todd Korthuis, E Jennifer Edelman

Abstract readEditorial
In one paragraph

Article in Addiction science & clinical practice, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Primary health care providers' views on managing substance use among people living with HIV.African journal of primary health care & family medicine · 2023
    Article
  14. Article
  15. The effect of substance uses on antiretroviral treatment adherence in primary health care.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

P Todd KorthuisDepartment of Medicine, Section of Addiction Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd., L475, Portland, OR, 97239-3088, USA. korthuis@ohsu.edu.
E Jennifer EdelmanYale University School of Medicine, New Haven, CT, USA.

Funding

The National Drug Abuse Treatment Clinical Trials NetworkUG1DA015831 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Roger D. Weiss · 2015 to 2026
$110.8M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Western States Node of the National Drug Abuse Treatment Clinical Trials Network (TMS for CUD) UG1DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Keith N. Humphreys, Philip Todd Korthuis · 2015 to 2026
$24.6M
Alcohol and Multisubstance Use in the Veterans Aging Cohort StudyU01AA020790 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2011 to 2020
$7.7M
Sex Disparities in Overall Response to ART Among HIV Infected IndividualsU24AA020794 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2011 to 2020
$5.5M
Integrated Stepped Care for Unhealthy Alcohol Use in HIVU01AA020795 · NIAAA · YALE UNIVERSITY · PI FIELLIN, DAVID · 2011 to 2020
$5.2M
Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study Cost ExtensionUH3DA044831 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI KORTHUIS, PHILIP TODD · 2019 to 2022
$4.0M
Working with HIV clinics to adopt addiction treatments using Implementation Facilitation (WHAT IF?)R01DA041067 · NIDA · YALE UNIVERSITY · PI FIELLIN, DAVID · 2015 to 2019
$2.9M
Buprenorphine to Improve HIV Care Engagement and Outcomes: A Randomized TrialR01DA037441 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI KORTHUIS, PHILIP TODD · 2013 to 2018
$2.7M
Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) StudyUG3DA044831 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI KORTHUIS, PHILIP TODD · 2017 to 2018
$895k
NCATS NIH HHS UL1 TR001863NIAAA NIH HHS U01 AA020790NIAAA NIH HHS U01 AA020795NIAAA NIH HHS U24 AA020794NIDA NIH HHS R01 DA037441NIDA NIH HHS R01 DA041067NIDA NIH HHS UG1 DA015815NIDA NIH HHS UG1 DA015831NIDA NIH HHS UG3 DA044831NIDA NIH HHS UH3 DA044831
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AlcoholismAnti-Retroviral AgentsContinuity of Patient CareHIV InfectionsHumansSubstance-Related DisordersAnti-Retroviral Agents

Identifiers

PMID29530080
PMCPMC5848588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.